Oh it's reality you want .... here you go:
1. FDA supports an accelerated approval pathway for Rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD) for a multi billion dollar blockbuster indication.
2. Mesoblast have a Pre BLA meeting scheduled with the FDA following the Type B meeting held with FDA on February 21, 2024 whereby the FDA were happy enough with the data from the phase 3 DREAM-HF the LVAD trials to support an Accelerated Approval (AA) pathway.
(You do understand what a BLA submission is for don't you ?)
3. Mesoblast secured a multi billion dollar partnership deal for CHF over a decade ago prior to the data from the DREAM-HF phase 3 trial data - you know the same data that the FDA said supports an AA pathway after their Type B meeting.... can you imagine what a CHF partnership deal looks like now with an RMAT Designation and the FDA supporting an AA pathway for same with the Pre BLA meeting happening in the near future?
https://www.genengnews.com/topics/t...last $130,adult stem cell technology platform.
Cephalon Shells Out $350M to Commercialize Mesoblast Stem Cell Therapies
Deal includes $130 million up front and a $220 million equity payment for a 19.99% stake in Aussie firm.
Cephalon is paying Mesoblast $130 million up front and will make a $220 million equity investment in the Australian firm as part of a collaboration to develop and commercialize adult mesenchymal precursor stem cell (MPC) therapies based on Mesoblast’s adult stem cell technology platform.
I could go on but clearly facts are wasted on you as you have a very limited understanding on what the FDA process is or what the developments mean for the company .... I can wait as I didn't invest in Mesoblast for sr-GVHD so if it gets approved it is just a bonus - the CHF indication is where the money is no matter what naysayers like yourself post on HC .... enjoy your day
- Forums
- ASX - By Stock
- MSB
- Pick Today's Price Range Low-High... Just for Fun
Pick Today's Price Range Low-High... Just for Fun, page-1130
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.56 |
Change
-0.010(0.64%) |
Mkt cap ! $1.764B |
Open | High | Low | Value | Volume |
$1.56 | $1.57 | $1.52 | $1.590M | 1.029M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 13611 | $1.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 27736 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 25934 | 1.565 |
9 | 17666 | 1.560 |
10 | 39089 | 1.555 |
13 | 192350 | 1.550 |
9 | 94973 | 1.545 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 56801 | 12 |
1.575 | 22724 | 4 |
1.580 | 46478 | 5 |
1.585 | 58359 | 2 |
1.590 | 47443 | 4 |
Last trade - 11.45am 18/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online